目次
オーラルセッション
- 第1日 5月15日（水） 14:45～15:25 C会場（101）
-
1C-O1-1445 PDF
LC/MSによるニューモダリティ定量の現状と課題
The trend in drug discovery and development is shifting towards biologics because of the decrease in productivity for small-molecule drug development. Therapeutic antibodies already have the largest market share in the current biopharmaceutical. Recently the therapeutic potential of new drug modalities such as peptide-based drugs, oligonucleotides and cell therapy is increasingly recognized and their development is aggressively conducted. LC/MS plays an important role in these fields, however, there remains various practical issues regarding quantification of targets. Therefore future technological innovation is highly needed even now.